Beijing Sanbo Brain Hospital Co., Ltd. (the “Company”, “Sanbo Brain Hospital”, or “Sanbo”), a nationally renowned neurosurgery hospital group in China, recently announced the completion of its RMB 800 million Series B equity financing round. This round of financing was led by Taikang Asset Management. Guangfa Xinde Investment, Hongding Investment, Park Road Medical Investment, CEC Capital Group’s Future Industry Fund, and others participated as followers.

Sanbo Brain Hospital was founded in 2004. After 16 years of development, it has become a nationally renowned medical group focused on neurosurgery in China. Sanbo operates 7 large hospitals (including 1 under construction) covering Beijing, Chongqing, Hunan, Fujian, Henan, and Yunnan. Its flagship hospital, Sanbo Brain Hospital of Capital Medical University, is one of the top neurological hospitals in China.

Since its establishment, Sanbo Brain Hospital has always adhered to the development principle and path of "integrating medicine, education, and research". It has been able to attract experts in neuromedicine including Luan Guoming, Yu Chunjiang, Shi Xiangen, Wang Baoguo, Yan Changxiang, Wu Bin, Lin Zhixiong, and Fan Tao, among others. These experts have decades of medical knowledge and clinical experience, and have developed modern medical concepts that have laid a solid foundation for the development of high-quality medical services, a platform for training talent, and the promotion of scientific research.

About CEC Capital Group

Founded in 2000, CEC Capital Group is one of China’s leading investment banks focusing on the three major industries of healthcare, consumer, and TMT. The company is headquartered in Beijing, with offices in Shanghai. Its US affiliate, China eCapital Partners, LLC, has offices in Los Angeles and San Francisco.

In the three years from 2017 to 2019, CEC Capital Group has participated in financing and M&A transactions valued at a total of more than RMB 100 billion. In addition to its investment banking business, CEC Capital Group has been managing an RMB fund and a USD fund since 2014.

About CEC Capital Group’s Future Industry Fund

CEC Capital Group’s Future Industry Fund is the first RMB fund established by CEC Capital Group, a leading investment bank in China. The Future Industry Fund focuses on growth investment opportunities in the areas of TMT, consumer, and healthcare. CEC Capital Group’s investment portfolio currently includes investments in China (Miss Fresh, Arrail Dental, and Universal Medical Imaging, among others) as well as in the US (Freenome). The Future Industry Fund currently operates out of offices in Beijing and Shanghai.